相似文献
1
Multiple Expressed Endogenous Glioma Epitopes as Novel Vaccines for Gliomas.
Clin Cancer Res. 2016 Oct 1;22(19):4760-4762. doi: 10.1158/1078-0432.CCR-16-1477. Epub 2016 Aug 12.
2
Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Clin Cancer Res. 2005 Aug 15;11(16):5900-11. doi: 10.1158/1078-0432.CCR-05-0559.
3
Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Cancer Res. 2003 Dec 1;63(23):8487-91.
4
Glioma antigen.
Adv Exp Med Biol. 2012;746:77-84. doi: 10.1007/978-1-4614-3146-6_6.
5
Autologous humoral response to human gliomas and analysis of certain cell surface antigens: in vitro study with the use of microcytotoxicity and immune adherence assays.
J Natl Cancer Inst. 1980 Feb;64(2):223-33. doi: 10.1093/jnci/64.2.223.
6
Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Int J Cancer. 2010 Feb 15;126(4):919-29. doi: 10.1002/ijc.24851.
7
Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination.
Clin Neurosurg. 2006;53:345-51.
8
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Cancer Immunol Immunother. 2019 Feb;68(2):331-340. doi: 10.1007/s00262-018-2274-1. Epub 2018 Nov 14.
9
[Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
Nihon Rinsho. 2002 Mar;60(3):497-503.
10
Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Scand J Immunol. 2009 Feb;69(2):80-9. doi: 10.1111/j.1365-3083.2008.02202.x. Epub 2008 Dec 10.
引用本文的文献
1
Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).
Brain Sci. 2021 Mar 18;11(3):386. doi: 10.3390/brainsci11030386.
2
Updated Insights on EGFR Signaling Pathways in Glioma.
Int J Mol Sci. 2021 Jan 8;22(2):587. doi: 10.3390/ijms22020587.
本文引用的文献
1
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Sci Transl Med. 2016 Jun 1;8(341):341ra75. doi: 10.1126/scitranslmed.aad9784.
2
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
Trends Immunol. 2016 Jul;37(7):462-476. doi: 10.1016/j.it.2016.04.010. Epub 2016 May 20.
3
Glioblastoma.
Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2.
4
Overview of current immunotherapeutic strategies for glioma.
Immunotherapy. 2015;7(10):1073-104. doi: 10.2217/imt.15.75.
5
Combination cancer immunotherapies tailored to the tumour microenvironment.
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58. doi: 10.1038/nrclinonc.2015.209. Epub 2015 Nov 24.
6
Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.
J Clin Oncol. 2015 Oct 1;33(28):3186-92. doi: 10.1200/JCO.2015.61.1525. Epub 2015 Aug 17.
7
Immune Checkpoint Blockade in Cancer Therapy.
J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20.
8
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.
Brain. 2012 Apr;135(Pt 4):1042-54. doi: 10.1093/brain/aws042. Epub 2012 Mar 14.
9
HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
PLoS Med. 2009 Jan 13;6(1):e10. doi: 10.1371/journal.pmed.1000010.
10
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors.
Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):427-31. doi: 10.1016/0360-3016(94)90432-4.
Zotero 插件